Raynaud Phenomenon Clinical Trial
Official title:
Nutritional Strategies to Increase Nitric Oxide Signaling in Raynaud's Phenomenon
The investigators aim at comparing the efficacy of a 2 weeks supplementation by L-citrulline or beetroot juice to L-citrulline placebo or denitrated beetroot juice respectively on Raynaud's phenomenon severity. Raynaud's phenomenon severity will be assessed through the Raynaud Condition Score, daily frequency of attacks or cumulative attack duration (expressed as min) daily collected by patients in a diary. Each Volunteer will choose his own main outcome among these 3 criteria.
Raynaud's phenomenon (RP) is a clinical condition that follows an exaggerated vasoconstriction of extremities in response to a cold or emotional stress. Microvascular dysfunction and alteration of the endothelial NO-dependent vasodilatation pathway through NO synthases (NOS) represents one of the main mechanisms. A pharmacological treatment in RP is proposed to patients when conservative measures are not efficient enough to control the symptoms: calcium channel blockers remains the first line, phosphodiesterase type 5 inhibitors as a second line treatment, while intravenous iloprost remains restricted to patients with digital ischaemia. Vasodilator therapies are commonly associated with side effects due to the non-specific systemic vasodilation that often result in permanent discontinuation. Many patients prefer complementary and alternative therapies, but none has proven its efficacy. Therefore, there is still room for improvement in the treatment of RP, and research is needed in this area. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03393325 -
Tadalafil-Delivra and Raynaud's Phenomenon
|
||
| Completed |
NCT03699436 -
Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon
|
N/A | |
| Enrolling by invitation |
NCT06291142 -
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
|
||
| Recruiting |
NCT03984422 -
Application for Monitoring and Evaluation of Raynaud's Phenomenon
|
||
| Recruiting |
NCT04015193 -
Follow-up of SPTS in Patients With Raynaud's Phenomenon
|
||
| Not yet recruiting |
NCT03972566 -
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
|
||
| Completed |
NCT04854850 -
Apollo Device for Fatigue in Systemic Sclerosis
|
N/A | |
| Completed |
NCT03129178 -
Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon
|
N/A | |
| Completed |
NCT04388176 -
Cold Challenge With C21 in RP
|
Phase 2 | |
| Completed |
NCT01280266 -
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
|
Phase 2/Phase 3 | |
| Completed |
NCT04644523 -
Dermoscopy in Primary Raynaud's Phenomenon
|
||
| Completed |
NCT03094910 -
Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon
|
N/A | |
| Recruiting |
NCT05204784 -
Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
|
N/A | |
| Recruiting |
NCT05125029 -
Botulinum Toxin in Raynaud's Phenomenon
|
Phase 4 | |
| Terminated |
NCT03639766 -
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
|
Phase 4 | |
| Withdrawn |
NCT04898036 -
Phototherapy For Treatment Of Raynaud's Phenomenon
|
N/A | |
| Terminated |
NCT03869008 -
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
|
N/A | |
| Recruiting |
NCT01347008 -
Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
|
Phase 3 |